Kristen M Sanfilippo1, Tzu-Fei Wang2. 1. Division of Hematology, Washington University School of Medicine, 660 S. Euclid Avenue, CB 8125, Saint Louis, MO, 63110, USA. ksanfilippo@wustl.edu. 2. Division of Hematology, The Ohio State University Comprehensive Cancer Center, A340 Starling Loving Hall, 320 W. 10th Avenue, Columbus, OH, 43210, USA.
Abstract
PURPOSE OF REVIEW: Patients with cancer have an increased risk of venous thromboembolism (VTE). Cancer-associated VTE is associated with an increased risk of morbidity and mortality. Treatment of VTE in cancer is associated with higher rates of recurrent thrombosis as well as major bleeding compared with the general population. The goal of this review is to provide a summary of current evidence for the prevention and treatment of cancer-associated VTE. RECENT FINDINGS: Validated risk prediction models are available to aide clinicians in identifying patients with cancer with the highest risk of VTE. Those patients with intermediate to high risk of VTE may benefit from primary prophylaxis with apixaban or rivaroxaban. Low-molecular-weight heparin is superior to vitamin K antagonists for the treatment of cancer-associated VTE. There is mounting evidence to support use of the direct oral anticoagulants for VTE in patients with cancer. Decisions on type and duration of anticoagulation in patients with cancer, either for primary or secondary prevention, should be made on a case-by-case basis with taking into account the individual patient bleeding and thrombotic risk.
PURPOSE OF REVIEW: Patients with cancer have an increased risk of venous thromboembolism (VTE). Cancer-associated VTE is associated with an increased risk of morbidity and mortality. Treatment of VTE in cancer is associated with higher rates of recurrent thrombosis as well as major bleeding compared with the general population. The goal of this review is to provide a summary of current evidence for the prevention and treatment of cancer-associated VTE. RECENT FINDINGS: Validated risk prediction models are available to aide clinicians in identifying patients with cancer with the highest risk of VTE. Those patients with intermediate to high risk of VTE may benefit from primary prophylaxis with apixaban or rivaroxaban. Low-molecular-weight heparin is superior to vitamin K antagonists for the treatment of cancer-associated VTE. There is mounting evidence to support use of the direct oral anticoagulants for VTE in patients with cancer. Decisions on type and duration of anticoagulation in patients with cancer, either for primary or secondary prevention, should be made on a case-by-case basis with taking into account the individual patientbleeding and thrombotic risk.
Entities:
Keywords:
Cancer-associated thrombosis; Direct oral anticoagulants; Primary prophylaxis; Secondary prophylaxis
Authors: Susan R Kahn; Wendy Lim; Andrew S Dunn; Mary Cushman; Francesco Dentali; Elie A Akl; Deborah J Cook; Alex A Balekian; Russell C Klein; Hoang Le; Sam Schulman; M Hassan Murad Journal: Chest Date: 2012-02 Impact factor: 9.410
Authors: Marc Carrier; Chris Cameron; Aurélien Delluc; Lana Castellucci; Alok A Khorana; Agnes Y Y Lee Journal: Thromb Res Date: 2014-10-08 Impact factor: 3.944
Authors: John A Heit; W Michael O'Fallon; Tanya M Petterson; Christine M Lohse; Marc D Silverstein; David N Mohr; L Joseph Melton Journal: Arch Intern Med Date: 2002-06-10
Authors: Gary H Lyman; Alok A Khorana; Anna Falanga; Daniel Clarke-Pearson; Christopher Flowers; Mohammad Jahanzeb; Ajay Kakkar; Nicole M Kuderer; Mark N Levine; Howard Liebman; David Mendelson; Gary Raskob; Mark R Somerfield; Paul Thodiyil; David Trent; Charles W Francis Journal: J Clin Oncol Date: 2007-10-29 Impact factor: 44.544
Authors: M Levine; J Hirsh; M Gent; A Arnold; D Warr; A Falanga; M Samosh; V Bramwell; K I Pritchard; D Stewart Journal: Lancet Date: 1994-04-09 Impact factor: 79.321
Authors: Annie M Young; Andrea Marshall; Jenny Thirlwall; Oliver Chapman; Anand Lokare; Catherine Hill; Danielle Hale; Janet A Dunn; Gary H Lyman; Charles Hutchinson; Peter MacCallum; Ajay Kakkar; F D Richard Hobbs; Stavros Petrou; Jeremy Dale; Christopher J Poole; Anthony Maraveyas; Mark Levine Journal: J Clin Oncol Date: 2018-05-10 Impact factor: 44.544